Clover Biopharmaceuticals Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program

Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific Advisory Board (SAB) comprised of internationally-renowned experts in the vaccine industry, public health and policy making. The SAB will provide strategic oversight and guidance to the global development of Clover’s protein-based COVID-19 S-Trimer vaccine programs.

Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, commented: “We are honored to welcome these leading vaccine experts to our newly-formed SAB. The SAB will provide a valued source of counsel as we continue to rapidly develop our COVID-19 S-Trimer vaccine. With a broad range of backgrounds, the SAB will serve a valuable role in advising Clover in all aspects of our global vaccine development and access in the critical months to come.”

Ralf Clemens, M.D., Ph.D., Chairman of the SAB, added: “I am pleased to lead this team of leaders

Read More